Gholam Pierre M, Iyer Renuka, Johnson Matthew S
Liver Center of Excellence, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue WRN5066, Cleveland, OH 44106, USA.
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14203, USA.
Cancers (Basel). 2019 Jun 22;11(6):873. doi: 10.3390/cancers11060873.
Hepatocellular carcinoma (HCC) is a leading cause of new cancer diagnoses in the United States, with an incidence that is expected to rise. The etiology of HCC is varied and can lead to differences between patients in terms of presentation and natural history. Subsequently, physicians treating these patients need to consider a variety of disease and patient characteristics when they select from the many different treatment options that are available for these patients. At the same time, the treatment landscape for patients with HCC, particularly those with unresectable HCC, has been rapidly evolving as new, evidence-based options become available. The treatment plan for patients with HCC can include surgery, transplant, ablation, transarterial chemoembolization, transarterial radioembolization, radiation therapy, and/or systemic therapies. Implementing these different modalities, where the optimal sequence and/or combination has not been defined, requires coordination between physicians with different specialties, including interventional radiologists, hepatologists, and surgical and medical oncologists. As such, the implementation of a multidisciplinary team is necessary to develop a comprehensive care plan for patients, especially those with unresectable HCC.
肝细胞癌（HCC）是美国新增癌症诊断的主要原因之一，其发病率预计还会上升。HCC的病因多种多样，这可能导致患者在临床表现和自然病程方面存在差异。因此，治疗这些患者的医生在从多种不同的可用治疗方案中进行选择时，需要考虑多种疾病和患者特征。与此同时，随着新的循证治疗方案的出现，HCC患者，尤其是不可切除HCC患者的治疗格局正在迅速演变。HCC患者的治疗方案可包括手术、移植、消融、经动脉化疗栓塞、经动脉放射性栓塞、放射治疗和/或全身治疗。在尚未确定最佳顺序和/或组合的情况下实施这些不同的治疗方式需要不同专业的医生之间进行协调，包括介入放射科医生、肝病学家以及外科和医学肿瘤学家。因此，有必要组建一个多学科团队，为患者，尤其是不可切除HCC患者制定全面的护理计划。
